Danaher (NYSE:DHR – Get Free Report) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, July 21st. Analysts expect the company to post earnings of $1.84 per share and revenue of $6.1059 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 21, 2026 at 8:00 AM ET.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.88 earnings per share. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Danaher Price Performance
Shares of NYSE:DHR opened at $203.65 on Monday. Danaher has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a 50-day moving average price of $183.27 and a 200 day moving average price of $198.25. The company has a market cap of $144.14 billion, a P/E ratio of 39.39, a PEG ratio of 2.51 and a beta of 0.79. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33.
Danaher Announces Dividend
Analyst Ratings Changes
A number of research firms recently weighed in on DHR. JPMorgan Chase & Co. decreased their price target on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. Piper Sandler started coverage on shares of Danaher in a research report on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Guggenheim lowered their price target on shares of Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Rothschild & Co Redburn set a $205.00 price target on shares of Danaher in a report on Friday, April 17th. Finally, Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $231.64.
Read Our Latest Stock Report on Danaher
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. Compound Planning Inc. lifted its holdings in shares of Danaher by 47.1% in the fourth quarter. Compound Planning Inc. now owns 9,554 shares of the conglomerate’s stock valued at $2,187,000 after purchasing an additional 3,060 shares in the last quarter. Invesco Ltd. increased its stake in shares of Danaher by 8.1% during the 4th quarter. Invesco Ltd. now owns 4,120,223 shares of the conglomerate’s stock worth $943,201,000 after purchasing an additional 307,095 shares in the last quarter. Birchwood Financial Partners Inc. acquired a new position in shares of Danaher during the 4th quarter worth approximately $41,000. Corient Private Wealth LLC lifted its stake in Danaher by 2.0% in the 4th quarter. Corient Private Wealth LLC now owns 1,025,570 shares of the conglomerate’s stock valued at $228,812,000 after buying an additional 19,852 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC purchased a new stake in Danaher in the 4th quarter valued at approximately $231,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
- Five stocks we like better than Danaher
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
